Expression of LEF1 in mantle cell lymphoma

Dennis P O'Malley1, John P Lee2, Andrew M Bellizzi2

  • 1Neogenomics, Aliso Viejo, CA, United States; Department of Hematopathology, M.D. Anderson Cancer Center/University of Texas, Houston, TX, United States.

Insights

LEF1 staining is a useful marker for differentiating small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL) from mantle cell lymphoma (MCL). However, rare cases of MCL can express LEF1, posing a diagnostic challenge.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Small lymphocytic lymphoma/chronic lymphocytic leukemia (CLL/SLL) and mantle cell lymphoma (MCL) are distinct lymphoid neoplasms.
  • Diagnostic differentiation is crucial for appropriate patient management.
  • LEF1 immunohistochemistry is highly sensitive for CLL/SLL, with rare reports in MCL.

Observation:

  • An index case of mantle cell lymphoma (MCL) with cyclin D1 expression and t(11;14) translocation was found to express LEF1.
  • LEF1 expression was assessed in 23 MCL cases, with one additional positive case identified.
  • Literature review suggests a 4-9% frequency of LEF1 expression in MCL.

Findings:

  • LEF1 expression in MCL is unusual but occurs rarely.
  • LEF1 positivity in MCL can mimic CLL/SLL, creating a diagnostic pitfall.
  • Immunohistochemical markers like cyclin D1 and SOX11 remain essential for MCL diagnosis.

Implications:

  • LEF1 should be interpreted cautiously in the differential diagnosis of MCL.
  • Awareness of LEF1 expression in MCL aids accurate diagnosis and classification.
  • Further studies are warranted to understand the biological basis of LEF1 expression in MCL.